The nation of Zimbabwe has declined a substantial American health deal valued at $367m (£272m) spanning five years over the United States' demand for confidential data.
This move was revealed following a official document dated December was leaked, indicating that Head of State Emmerson Mnangagwa felt the deal was "unbalanced".
A government spokesman later explained that the US was seeking health data for scientific study and profit while was unwilling to guarantee the benefits from future medical innovations.
"We are forced to start the difficult and regrettable process of scaling back our support in Zimbabwe," said American envoy to Zimbabwe Pamela Tremont publicly.
The US Embassy noted the United States had donated more than $1.9bn for health programmes to Zimbabwe during the past two decades.
A physicians' group in Zimbabwe has urged continued negotiations to secure a agreement agreeable to both sides so the country's critical HIV treatment initiative can be sustained.
Wider Background
Zimbabwe's decision follows a similar case in neighbouring Kenya, where a court suspended a related deal with the US after concerns were raised about the safety of Kenyans' health data.
Since returning to office recently, US President Donald Trump has reduced overseas assistance and closed the key foreign aid agency.
The agency had administered aid for the US government, but Trump stated its expenditure was "wasteful" and his government was pursuing government-to-government deals to boost openness and responsibility.
According to reports, Sixteen African countries have to date signed similar agreements, constituting over $18.3bn in committed funds.
Details of the Declined Deal
The money for Zimbabwe was intended to supported "tackling HIV/Aids, tuberculosis, malaria, healthcare for mothers and children, and preparing for epidemics".
"We believe this partnership would have delivered extraordinary benefits for the people of Zimbabwe, especially the 1.2 million men, women and children presently on HIV treatment via US-supported initiatives," Tremont said.
However, official spokesman Nick Mangwana maintained the proposed deal was "unequal".
"The proposal required Zimbabwe to provide its genetic material and health information for a long time, with no corresponding promise of benefiting from any scientific breakthroughs – like vaccines, diagnostics, or treatments – that might be developed from that provided information," Mangwana explained.
"Effectively, our nation would supply the basic resources for medical research without any certainty that the end products would be accessible to our population if a new pandemic emerge."
National Interest and Global Health
He also said that the US's withdrawal from the global health body and its push of bilateral deals were undermining frameworks already set up via the global organization.
The spokesperson gave as an example its Pathogen Access and Benefit Sharing framework designed to manage future global health emergencies.
"This mechanism is designed to guarantee that when a country contributes its data, the resulting advantages – including medicines and cures – are distributed fairly, not monopolised solely by those with the funds to create them."
The government's concerns over the US deal "must not be interpreted as opposition to America," Mangwana stressed.
"We welcome further dialogue with our American counterparts on how future collaboration could be arranged in a manner that respects the independence and interests of each country."
Medical Community Reaction
A leading public health body expressed it recognised the government's concerns, but urged that negotiations must proceed given that much of the country's HIV programmes depended on international support.
"If technical issues arise, including those relating to data governance or agreement terms, these can often be resolved via detailed discussion and mutually agreed protections," the group commented.
The situation underscores the continuing challenges between receiving crucial foreign assistance and protecting local interests in an ever more data-driven world.